Thomas F. Gajewski to Mutation
This is a "connection" page, showing publications Thomas F. Gajewski has written about Mutation.
Connection Strength
0.687
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.309
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
Score: 0.076
-
WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
Score: 0.072
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.060
-
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
Score: 0.054
-
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
Score: 0.049
-
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011 Apr; 38(2):236-42.
Score: 0.042
-
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
Score: 0.013
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137.
Score: 0.012